Novo Nordisk to present data from ‘key semaglutide clinical trials’ at ADA

Novo Nordisk announced the presentation of 34 abstracts “highlighting the breadth of its portfolio” at the upcoming 84th Scientific Sessions of the American Diabetes Association, or ADA, which will be held in-person and virtually from June 21-24 in Orlando. All abstracts will be published on the website of the journal Diabetes. Data from the scientific sessions will be made available after their presentation, the company noted. “Additional data from three landmark trials with semaglutide will also be presented in dedicated scientific sessions. The trials assess additional potential benefits of semaglutide, including evaluation of kidney and cardiovascular endpoints in people with type 2 diabetes and chronic kidney disease and cardiovascular and glucose-related endpoints in people with obesity and CVD, with and without diabetes,” the company stated. “We recognise that cardiometabolic conditions like cardiovascular disease, chronic kidney disease, obesity and type 2 diabetes are often interlinked and might occur in the same patient. We need to develop medicines that address multiple facets of the diseases. The broad data being presented this year at ADA reflect this goal. In particular, data from FLOW and SELECT look at ways to treat common comorbidities of diabetes and obesity, such as kidney disease and cardiovascular disease,” said Stephen Gough, senior vice president and global Chief Medical Officer at Novo Nordisk.